RxDoctor Payments Data
★ My doctorsLook up a doctor →

Kevin Windsor

Hematology & Oncology · Birmingham, ALNPI 1801828405

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $8,956 of the $12,767 with a category attached, or 70.1%. It is spread thinly across 59 manufacturers, the largest accounting for just 17.2%. Reporting peaked in 2020 at $5,709 and has fallen 99.2% since, to $44 in 2025.

$12,767in general payments, 2019–2025

Across 566 payments — averaging $22.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$2K
  • Bristol Myers Squibb$1K
  • Rigel Pharmaceuticals, Inc.$1K
  • Amgen$1K
  • Merck$643
  • AstraZeneca$595
  • plus $6K from 53 others
$95,750in research payments, 2019–2025

Across 4 payments — averaging $23,938 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • E.r. Squibb & Sons, L.L.C.$96K

What the payments were for

  • Consulting fees$2,66821%
  • Speaking & faculty fees$1,0008%
  • Food & beverage$8,95670%
  • Education$1441%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech USA, Inc.26$2,191
Bristol Myers Squibb17$1,122
Rigel Pharmaceuticals, Inc.4$1,043
Amgen52$1,019
Merck41$643
AstraZeneca(2 entities)39$595
Novartis31$567
Seagen Inc.31$465
Johnson & Johnson(2 entities)27$443
Takeda Pharmaceuticals U.S.A., Inc.32$440
E.r. Squibb & Sons, L.L.C.31$428
Pfizer21$277
Eisai Inc.15$270
Incyte Corporation13$240
Pharmacyclics LLC, An Abbvie Company16$236
Daiichi Sankyo Inc.14$227
Exelixis Inc.14$221
AbbVie9$179
Gilead(2 entities)11$159
Lilly USA, LLC13$156
Bayer9$150
GSK8$125
Boehringer Ingelheim5$109
Sanofi5$99
Epizyme, Inc.5$91
Regeneron Healthcare Solutions, Inc.5$85
Deciphera Pharmaceuticals Inc.4$85
Puma Biotechnology, Inc.4$63
Array Biopharma Inc4$62
Kyowa Kirin, Inc.4$60
Astellas Pharma US Inc4$58
Dova Pharmaceuticals3$57
Blueprint Medicines Corporation3$52
Beigene USA, Inc.3$50
Karyopharm Therapeutics Inc.3$50
Taiho Oncology, Inc.3$47
Octapharma USA, Inc.2$46
Helsinn Therapeutics (U.S.), Inc.3$44
Ipsen Biopharmaceuticals, Inc2$42
Pharmacosmos Therapeutics Inc.2$40
Sobi, Inc1$38
AVEO Pharmaceuticals, Inc.2$35
Acrotech Biopharma Inc.2$32
Myriad Genetic Laboratories, Inc.2$31
EMD Serono, Inc.2$29
Myovant Sciences Inc.2$28
Morphosys, US Inc.2$28
Boston Scientific2$28
Tesaro, Inc.1$25
Shire North American Group Inc1$18
Clovis Oncology, Inc.3$18
Adaptive Biotechnologies Corporation1$18
Novocure Inc.1$17
Jazz Pharmaceuticals Inc.1$16
Verastem, Inc.1$16
AMAG Pharmaceuticals, Inc.1$14
Sandoz1$14
Lexicon Pharmaceuticals, Inc.1$13
TG Therapeutics, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,767 in reported general payments places this provider in the 65th percentile of 177 hematology & oncology providers in Alabama.

See all hematology & oncology providers in Alabama →

Other hematology & oncology in Birmingham

See the full list for Alabama →

Where these figures come from

Is this you, or does something look wrong? →